What is monoclonal antibody humanization?

Monoclonal antibody humanization reduces non-human sequence content while aiming to preserve the antibody’s antigen-binding properties. ProteoGenix offers both AI-guided humanization and classical CDR grafting for monoclonal antibodies, depending on the molecule and project requirements.

How does your AI-guided antibody humanization service work?

Our AI-guided workflow combines humanized variant generation with bioinformatician review, multi-criteria candidate ranking and experimental validation. AIxplore® is used during the design stage, while ProteoGenix experts review the generated candidates before selected variants progress to recombinant production and wet-lab testing.

How long does antibody humanization take?

Our AI-guided antibody humanization workflow takes 3–4 weeks, saving approximately 5 weeks compared with our classical CDR-grafting route, which takes approximately 9 weeks. Additional characterization or optimization services may extend the overall project timeline.

What should I look for in an antibody humanization service provider?

When selecting an antibody humanization service provider, consider how candidates are designed and selected, whether human experts review computational outputs, how binding is experimentally validated, whether developability is considered early, and who owns the resulting sequences. ProteoGenix combines AI-guided design, expert review, recombinant production and wet-lab validation, with 100% ownership of the resulting humanized sequences.

Can you humanize different antibody formats?

Yes. The humanization strategy can be adapted to different antibody formats, including monoclonal IgG, VHH, Fab, scFv and bispecific antibodies, according to the molecule’s architecture, species origin and project objectives.

Do I need to provide the VH/VL sequences to start a humanization project?

No. If the parental VH/VL sequences are already available, the project can start from those sequences. If not, ProteoGenix can begin with parental antibody sequencing. Under our no sequence, no fee guarantee, if we cannot determine the VH/VL sequences of your antibody, you are not charged.

How many humanized antibody variants do you generate?

With the AI-guided approach, ProteoGenix can generate up to 22 humanized variants for candidate evaluation. The classical CDR-grafting route provides 18 variants. Candidate selection depends on the humanization strategy and project requirements.

How do you evaluate humanized antibody candidates?

Humanized candidates are assessed through computational ranking and experimental testing. Development-related criteria are considered during AI-guided candidate selection, and selected variants progress to recombinant production and wet-lab evaluation. The workflow includes ELISA with BSA control, while SPR/BLI, SEC-HPLC, nanoDSF and DLS can be used when required by the project.

What do I receive at the end of an antibody humanization project?

Project deliverables can include the humanized antibody sequences, purified recombinant antibodies, production and quality-control data, experimental binding results and a detailed project report, according to the selected workflow.

Can you continue with affinity maturation or developability optimization after humanization?

Yes. Selected humanized candidates can progress to further antibody engineering and characterization, including affinity maturation, developability optimization and additional recombinant antibody production or downstream development services.

Who owns the IP of the humanized antibody sequences?

You retain 100% ownership of the resulting humanized antibody sequences and project results, with no royalties or milestone payments.

Antibody Humanization Services

AI-guided design, expert review and wet-lab validation in 3–4 weeks.

Humanize monoclonal antibodies with AI-guided design, expert review and experimental validation.

5 weeks saved vs. classical CDR grafting
Developability considered during variant selection
100% success rate – at least one variant matching parental binding
No win, no fee.

Discuss Your Project See How Our AI Humanization Works ↓

Classical CDR grafting is also available.

Our AI approach

AI-Powered Antibody Humanization, From Design to Wet-Lab Validation

Our AI-powered approach combines computational design with human expertise and experimental validation to accelerate antibody humanization.

The AI design step is powered by AIxplore®, our proprietary antibody engineering AI platform.

01

AI Generation

Humanized antibody variants are generated using our proprietary AI platform, AIxplore®.
02

Bioinformatician Review

Every AI output is checked by a ProteoGenix bioinformatician before production.
03

Developability Ranking

Each variant is ranked on several criteria, including developability, to support candidate selection.
04

Wet-Lab Validation

Selected humanized variants are produced and experimentally tested in the wet lab.

The result: 5 weeks saved on your project | Up to 22 humanized variants

⚠️ Developability is considered during AI design, not only after humanization!

Multi-criteria variant ranking

Avoid Investing in Antibody Variants That May Fail During Development

During AI-guided design, each variant is ranked across multiple development-related criteria to help prioritize stronger candidates before recombinant production and downstream testing.

Developability-Aware Ranking

Development-related properties are considered during candidate selection, rather than only after humanization.
Earlier Candidate Prioritization

Multi-criteria ranking helps identify stronger candidates before investing in recombinant production and downstream testing.
Human expertise

AI-generated candidates are reviewed by ProteoGenix experts before they progress to production and wet-lab evaluation.

Criteria considered during candidate selection

Manufacturability
Solubility and aggregation
Stability
Immunogenicity
Chemical liabilities
Toxicity

Have a challenging antibody? Discuss your humanization strategy →

Antibody Humanization Workflow in
3–4 Weeks

See how your antibody progresses from sequence analysis and AI-guided design to experimental validation.

01

Parental Antibody Sequencing

VH/VL sequence identification and CDR annotation from the source antibody.
02

Chimeric Antibody Expression & Purification

Expression in XtenCHO™ cells, followed by purification and quality control.
03

AI-Driven Design With AIxplore®

Humanized sequences are generated using human germline selection and structural analysis, with candidates ranked on binding-related and developability criteria.
04

Go / No-Go Checkpoint

You review the project report and confirm which variants move forward to recombinant production.
05

Variant Production

Selected humanized variants are produced using the high-throughput expression workflow and purified via XtenCHO-Race™.
06

Variant Analysis

The top 3 variants are evaluated by ELISA and BSA control. Optional analyses include SPR/BLI, SEC-HPLC, nanoDSF and DLS.

The exact workflow can be adapted to your starting material and project stage, including projects that already have VH/VL sequences.

Project deliverables

Antibody Humanization Deliverables

You receive the sequences, experimental material and project data needed to compare humanized candidates and continue antibody development.

Up to 22 Humanized Variants

AI-generated humanized antibody variants, with a design target of at least 80% identity.
Purified Recombinant Antibody Samples

Recombinant humanized antibody samples for experimental comparison and downstream testing.
Experimental & QC Data

Production yields, quality-control information and ELISA data, with additional assays available depending on the project.
Detailed Report + Full IP Ownership

Generated sequences, production and analytical data are compiled in the final report. Full IP ownership is transferred to you, with no royalties or milestone payments.

Ready to evaluate your antibody for humanization?
Share your sequence or project details with our antibody team.
Discuss Your Project

Further antibody optimization

Continue From Antibody Humanization to Further Optimization

Extend the humanization project with additional antibody optimization and recombinant production services without switching providers.

Developability Improvement

Further design and testing for manufacturability, stability, aggregation and related liabilities.
Affinity Maturation

Optimization of target binding after humanization.
High-Throughput Antibody Production

Recombinant production and purification of selected antibody candidates.

Case report

AI-Guided Humanization for a Cervical Cancer Therapeutic Antibody

A French biotechnology company partnered with ProteoGenix to humanize a therapeutic antibody while preserving key structural features and evaluating binding after humanization.

22

humanized variants designed with AIxplore®
>80%

human sequence identity achieved for most variants
Structure preserved

VH/VL quaternary architecture and paratope conformational dynamics were preserved
Up to 2.6×

higher ELISA binding versus the parental antibody in several variants

ELISA binding assay comparison graph showing 2.6x higher binding affinity of AIxplore humanized antibody variants compared to the parental mouse antibody for cervical cancer therapy
See the case report

Antibody formats

We Adapt to Multiple Antibody Formats

The humanization workflow can be adapted to the architecture and species origin of different antibody molecules.

Conventional IgG
VHH
Fab fragments
scFv
Bispecific formats

Scientific track record

Antibody Humanization Track Record: Patents and Clinical Programs

Examples of antibody programs associated with ProteoGenix humanization and downstream antibody development work.

Alzinova AB — Sweden

Patent WO2024194298A1 — humanized antibody behind ALZ-201, targeting toxic Aβ42 oligomers for Alzheimer’s disease. ProteoGenix also developed the stable cell line.

CIS Biopharma AG — Switzerland

Patent WO2024100200A1 — antibody behind CBO-001, an antibody-drug conjugate targeting L1-CAM (CD171) for aggressive cancers.

ImmuneWalk Therapeutics — Israel

IW-601 targets MOSPD2. The source page states that Phase 1 was completed with positive safety, PK and mechanistic data, with Phase 2 expected in 2027.

Prof. Richard Kremer — McGill University

Antibodies against PTHrP for breast and pancreatic cancer, with work published in Cancer Discovery (2021) and the Journal of Clinical Investigation.

Inhibitec Anticuerpos SL — Spain

A murine monoclonal antibody targeting BAMBI for psoriasis and psoriatic arthritis.

Reduce-immunogenicity-with-our-humanization-service

Classical antibody humanization

Classical CDR Grafting Antibody Humanization

ProteoGenix also offers classical CDR grafting, the conventional antibody humanization approach used across the industry for decades and our most established route to date.

Established CDR-grafting approach
Parental CDR loops are grafted onto human germline-derived frameworks.
≥80% human germline identity design target
Humanized variants are designed toward the same human germline identity target.
No sequence, no fee guarantee
If we cannot determine the VH/VL sequences of your antibody, you are not charged.

Discuss Classical CDR Grafting →

Compare humanization methods

AI-Guided Antibody Humanization vs
Classical CDR Grafting

Compare the two humanization routes by design approach, number of variants, developability integration and project timeline.

Criterion	Classical CDR Grafting	AI-Guided Humanization
Design principle	Parental CDRs grafted onto human frameworks, with back-mutations where needed	Germline-guided redesign supported by AI and structural analysis
Germline selection	Expert-selected frameworks	Human germlines screened and evaluated during AI-guided design
Structural analysis	Case-by-case modeling	Structural analysis integrated before production
Variants	18	Up to 22
Developability approach	Separate optional step	Criteria considered during candidate ranking
Turnaround	9 weeks	3–4 weeks
Expert review + wet-lab validation	Yes	Yes
Guarantee	No win, no fee	No win, no fee

FAQ

Monoclonal antibody humanization reduces non-human sequence content while aiming to preserve the antibody’s antigen-binding properties. ProteoGenix offers both AI-guided humanization and classical CDR grafting for monoclonal antibodies, depending on the molecule and project requirements.
Our AI-guided workflow combines humanized variant generation with bioinformatician review, multi-criteria candidate ranking and experimental validation. AIxplore® is used during the design stage, while ProteoGenix experts review the generated candidates before selected variants progress to recombinant production and wet-lab testing.
Our AI-guided antibody humanization workflow takes 3–4 weeks, saving approximately 5 weeks compared with our classical CDR-grafting route, which takes approximately 9 weeks. Additional characterization or optimization services may extend the overall project timeline.
When selecting an antibody humanization service provider, consider how candidates are designed and selected, whether human experts review computational outputs, how binding is experimentally validated, whether developability is considered early, and who owns the resulting sequences. ProteoGenix combines AI-guided design, expert review, recombinant production and wet-lab validation, with 100% ownership of the resulting humanized sequences.
No. If the parental VH/VL sequences are already available, the project can start from those sequences. If not, ProteoGenix can begin with parental antibody sequencing. Under our no sequence, no fee guarantee, if we cannot determine the VH/VL sequences of your antibody, you are not charged.
Humanized candidates are assessed through computational ranking and experimental testing. Development-related criteria are considered during AI-guided candidate selection, and selected variants progress to recombinant production and wet-lab evaluation. The workflow includes ELISA with BSA control, while SPR/BLI, SEC-HPLC, nanoDSF and DLS can be used when required by the project.

Start your antibody humanization project

Discuss Your Antibody Humanization Project

Tell us about your antibody and project requirements. Our antibody engineering team will review your request and recommend the appropriate humanization strategy.

AI-guided humanization or classical CDR grafting
Start from VH/VL sequences or parental antibody sequencing
Upload sequence data or supporting documents if available
No sequence file is required to start the discussion

Already have VH/VL sequences? Send them with the form.
Starting from a hybridoma? The project can begin with parental antibody sequencing.

Antibody Humanization Services

AI-Powered Antibody Humanization, From Design to Wet-Lab Validation

AI Generation

Bioinformatician Review

Developability Ranking

Wet-Lab Validation

Avoid Investing in Antibody Variants That May Fail During Development

Developability-Aware Ranking

Earlier Candidate Prioritization

Human expertise

Antibody Humanization Workflow in 3–4 Weeks

Parental Antibody Sequencing

Chimeric Antibody Expression & Purification

AI-Driven Design With AIxplore®

Go / No-Go Checkpoint

Variant Production

Variant Analysis